| CRINETICS PHARM. DL-,001 |
| USA |
| Gesundheit |
| US22663K1079 / A2JQTJ |
| 6Z4 (Frankfurt) / CRNX (NASDAQ) |
| FRA:6Z4, ETR:6Z4, 6Z4:GR, NASDAQ:CRNX |
| - |
| https://www.crinetics.com.. |
|
Crinetics Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics for rare endocrine diseases and endocrine-related tumors. Its proprietary p..
>Volltext.. |
| 3892.99 Mio. EUR |
| 2817.18 Mio. EUR |
| 15.8 Mio. EUR |
| -473.53 Mio. EUR |
| -433.99 Mio. EUR |
| -4.49 EUR |
| 41.84 Mio. EUR |
| 99.97 Mio. EUR |
| -362.11 Mio. EUR |
| 18.17 |
| 4586.76% |
| -41.6% |
| - |
| - |
| - |
| CRINETICS |
| 06.07.26 |
|